Search

KW-7158

The therapeutic effects of KW-7158 in overactive bladder may be due to the activation of A-type K(+) channels which regulate afferent neuron excitability and firing properties in the dorsal root ganglion … KW-7158 is a tricyclic compound with a non-cholingergic mechanism of action for the treatment of "urinary urgency," "frequent urination" and "urinary incontinence" associated with bladder overactivity

Tozuleristide

Tozuleristide is under investigation in clinical trial NCT02464332 (Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery).

Pipotiazine

However, it produces a high incidence of extra pyramidal reactions. It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. … Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics.

Triacetin

Ellagic acid

In pomegranates, there are several therapeutic compounds but ellagic acid is the most active and abundant. Ellagic acid is also present in vegetables. … Ellagic acid is present in several fruits such as cranberries, strawberries, raspberries, and pomegranates.

SPC2968

It was under investigation in clinical trial NCT02564614 (A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult … SPC2968 is a synthetic antisense oligodeoxynucleotide targeting hypoxia-inducible factor-1alpha (HIF-1alpha).

Sodium borate

Estradiol acetate

in potency and in estrogenic effects. … Because of the difference in potency between estradiol and estrone, menopause (and a change in primary hormone from estradiol to estrone) is associated with a number of symptoms associated with this reduction

Grapiprant

[A39838] This type of molecules is currently in development for veterinary patients.[A39816] This class of drugs was defined in 2013 by the World Health Organization. … [L4766] Grapiprant has been approved in March 2016 by the FDA's Center for Veterinary Medicine as a non-cyclooxygenase inhibiting NSAID for veterinary use.[A39836]

Fluoroazomycin arabinoside F-18

Fluoroazomycin arabinoside F-18 is under investigation in clinical trial NCT03257150 (A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer).